MC4R and obesity disorder: For instance, the non-selective agonist bremelanotide has been shown to induce elevated blood pressure in clinical trial for male and female sexual dysfunction, while the MC4R selective peptide agonist setmelanotide (10-fold over MC3R) have shown no adverse effects on either blood pressure or heart rate in an anti-obesity study (Ju et al., 2018).